Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
Conditions
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndromes
- Myeloproliferative Overlap Neoplasms
- Chronic Neutrophilic Leukemia
Interventions
- DRUG: Momelotinib
- DRUG: Azacitidine
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators